Tuğba Başoğlu, Associate Professor and Medical Oncologist at Kartal Dr. Lutfi Kirdar City Hospital, shared a post on X about a paper by E. Vita et al. published in ESMO Open:
“New data in ESMO Open:
In EGFR+ NSCLC treated with 1L osimertinib, concurrent NRG1 variants of uncertain significance (VUS) are an independent poor prognostic factor.
- PFS: 26.1 vs 12.1 mo
- OS: 34.1 vs 20.5 mo.”
Title: Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib
Authors: E. Vita, A. Scala, A. Vitale, L. Mastrantoni, J. Evangelista, F. D’Auria, A. Stefani, F. Monaca, J. Russo, G. Horn, P. Troisi, A. Cosmai, S. Polidori, M. Di Salvatore, E. De Paolis, A. Minucci, C. Nero, R. Trisolini, A. Cancellieri, G. Scambia, G. Tortora, E. Bria
You can read the Full Article in ESMO Open.
More posts featuring Tuğba Başoğlu.